Biogen Idec Inc., of Cambridge, Mass., appointed Faheem Hasnain senior vice president of its oncology strategic business unit.

Dendreon Corp., of Seattle, appointed Rick Hamm senior vice president and general counsel.

Diversa Corp., of San Diego, appointed Anthony Altig senior vice president of finance and chief financial officer.

enGene Inc., of Vancouver, British Columbia, appointed Hector MacKay-Dunn and Jack Wood to its board.

Enzon Pharmaceuticals Inc., of Bridgewater, N.J., appointed Goran Ando and Victor Micati to its board.

Eyetech Pharmaceuticals Inc., of New York, appointed Barrett Katz vice president of medical strategy.

GenoMed Inc., of St. Louis, appointed Werner Dubitzky to its science advisory board.

GenVault, of San Diego, appointed Roderick Westrop director of sales, Europe.

Gloucester Pharmaceuticals Inc., of Cambridge, Mass., appointed William McCulloch executive vice president and chief medical officer, and John McBride executive vice president and chief operating officer.

Helix BioMedix Inc., of Bothell, Wash., appointed Barry Seidman to its board.

Immtech International Inc., of Vernon Hills, Ill., appointed Daniel Schmitt director of commercial development.

Integrated Pharmaceuticals Inc., of Fitchburg, Mass., appointed Sally Johnson-Chin to its board.

Labopharm Inc., of Laval, Quebec, appointed Ian Lennox to its board.

MedImmune Inc., of Gaithersburg, Md., appointed Francois Lebel vice president of medical affairs.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed John Bishop vice president of pharmaceutical sciences and manufacturing, and Michael Lawless senior director of investor relations.